Our Active Immunotherapy Medicine (AIM) platform is designed to harness the immune system to convert the body into its own natural “drug factory” stimulating the production of antibodies.

AIM technology uses synthetic peptides to mimic and optimally combine biological epitopes to selectively activate the immune system and overcome “immune tolerance”, or the body’s tendency to avoid attacking self-molecules. Conventional vaccine technologies have to date fallen short in attempts to achieve this due to insufficient responses and side effects. In cases of infectious disease, we can integrate AIM peptides with recombinant proteins to stimulate both B-cell and T-cell responses to pathogens such as viruses.

The AIM platform has been scientifically validated, with billions of doses commercialized in animal health, and 10 human clinical trials successfully completed. AIMs can be stored and shipped at conventional cold chain temperatures (2-8°C), requiring no special frozen cold chain infrastructure, making them more easily affordable and scalable.